14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
GRML vs PROK: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, ProKidney Corp. Class A (PROK) is the stronger overall head-to-head candidate over GRML (GRML) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). GRML carries a Unified Composite Score of 56.8/100 (HOLD) at $3.50 (N/M Forward P/E, N/A operating margin), whereas PROK carries 54.0/100 (HOLD) at $1.04 (N/M Forward P/E, -24830.3% operating margin).
Composite vs. Pillar Nuance: While GRML currently prints a higher short-term Unified Composite Score (56.8/100 HOLD vs. PROK 54.0/100 HOLD), PROK captures the overall institutional head-to-head verdict (6–2 matrix metrics and 4–0 across the 6 pillars) due to superior fundamental profitability (-24830.3% vs. N/A operating margin) and revenue trajectory (-19.8% vs. N/A YoY).
Technical & Structure Timing Caution: GRML trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 37.5); meanwhile PROK is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 32.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on GRML vs PROK. Trailing 12-month operating profitability (GRML N/A vs PROK -24830.3%) and valuation multiples (GRML N/M vs PROK N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $415.2M market capitalization and -24830.3% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ GRML vs PROK Key Questions & Quantitative Answers
As of Nov 16, 2026, ProKidney Corp. Class A (PROK) is the stronger overall head-to-head candidate over GRML (GRML) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). GRML carries a Unified Composite Score of 56.8/100 (HOLD) at $3.50 (N/M Forward P/E, N/A operating margin), whereas PROK carries 54.0/100 (HOLD) at $1.04 (N/M Forward P/E, -24830.3% operating margin). Composite vs. Pillar Nuance: While GRML currently prints a higher short-term Unified Composite Score (56.8/100 HOLD vs. PROK 54.0/100 HOLD), PROK captures the overall institutional head-to-head verdict (6–2 matrix metrics and 4–0 across the 6 pillars) due to superior fundamental profitability (-24830.3% vs. N/A operating margin) and revenue trajectory (-19.8% vs. N/A YoY). Technical & Structure Timing Caution: GRML trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 37.5); meanwhile PROK is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 32.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
PROK leads the Growth & Scale pillar: GRML posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with PROK at -19.8% YoY revenue growth and +0.0% YoY earnings growth on $775,000 TTM revenue (100.0% gross margin, -24830.3% operating margin). On trailing 12-month operating scale, GRML generates N/A in USD-normalized revenue versus $775,000 for PROK. In operating R&D and SG&A reinvestment, GRML deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for PROK.
GRML and PROK trade at balanced relative valuation multiples. GRML trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas PROK trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against GRML (N/A ROE) versus PROK (-73.4% ROE) capital efficiency.
In options market volatility and institutional positioning, GRML carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-5.29β · 95% Vol realized risk). By comparison, PROK carries 364.9% implied volatility (42nd %ile, Balanced (25th–60th %ile)), a 0.83x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.68β · 92% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.